AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$66.15M

FY 2025 · Annual

Investing Cash Flow

$60.69M

FY 2025 · Annual

Financing Cash Flow

-$974,143.00

FY 2025 · Annual

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$67.3M
+ D&A$2.4M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$6.5M
+ Other Non-Cash$5.2M
= Operating Cash Flow-$66.1M
- Capex-$859.5K
= Free Cash Flow-$67.0M

Analysis

FY2025 free cash flow is -$67.0M. FCF conversion is 99.6% of net income. Operating cash flow was -$66.1M, with capex of -$859.5K. The largest bridge item is Working Capital at -$6.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 4, 2026
3Initial statement of beneficial ownershipOct 9, 2026
3/A3/A filingOct 9, 2026
6-K6-K filingOct 2, 2026
6-K6-K filingSep 23, 2026

Does ACIU generate free cash flow?

AC Immune S.A. (ACIU) generated -$67.01M of free cash flow in fiscal 2025.

How much operating cash flow does ACIU produce?

Operating cash flow was -$66.15M, before capital expenditures of $859,541.00.